通过基于生理学的药理动力学建模来评估通用生物等价性研究中的性别影响 - 德克斯特罗梅索芬修饰释放片的案例研究
Manoj Gundeti1, Aditya Murthy2, Shubham Jamdade1
1Global Clinical Management, IPDO, Dr Reddy's Laboratories Ltd, Hyderabad, India.
Biopharmaceutics & drug disposition
|May 22, 2024
概括
通用药物生物等价性 (BE) 研究往往低于女性. 基于生理学上的药理动力学 (PBPK) 建模评估了德克斯特罗梅索芬性能上的性别影响,显示了放弃额外研究和更快地进入市场的潜力.
科学领域:
- 药理动力学和药物新陈代谢
- 监管科学 监管科学
- 计算生物学 计算生物学
背景情况:
- 监管指南建议在仿制药的生物等价性 (BE) 研究中男性和女性的代表性平等.
- 仿制药公司往往未能满足这些建议,因为影响女性参与的社会经济和文化因素.
- 监管机构越来越多地要求进行额外的研究,以评估代表性不足的性别的药物性能.
研究的目的:
- 通过使用生理学基础的药理动力学 (PBPK) 建模,评估德克斯特罗梅索芬修饰释放片对表现的性别影响.
- 使用PBPK模拟,在不同性别人口场景中比较药物产品的性能.
- 探索PBPK建模的潜力,以支持对仿制药的生物等价性研究豁免.
主要方法:
- 用生理学基础的药理动力学 (PBPK) 建模来模拟药物性能.
- 人口药理动力学 (PK) 模拟针对四种情景进行:全男性,全女性,50:50男性:女性,70:30男性:女性.
- 虚拟生物等价性 (BE) 评估是通过将模拟数据与全男性参考研究进行比较来进行的.
主要成果:
- PBPK建模表明,男性和女性群体之间的德克斯特罗梅索芬性能存在差异.
- 模拟显示,在测试的性别场景中,药物产品的性能具有不同程度的相似性/差异性.
- 这项研究成功地使用了PBPK来虚拟评估与性别相关的绩效差异.
结论:
- 基于生理学的药理动力学 (PBPK) 建模可以有效地评估生物等价性研究中的性别特异性药物性能.
- 这种建模方法提供了一个潜在的策略,以证明生物等价性研究豁免,降低成本和加速仿制药进入市场.
- 通过建模来解决BE研究中女性代表性不足的问题,可以确保药物在不同人群中的有效性.
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
69
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
69
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Factors Affecting Drug Biotransformation: Biological
142
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
142
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
124
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
124
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38
Model Approaches for Pharmacokinetic Data: Physiological Models
41
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
41


